Schedules of Controlled Substance: Temporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule I
DEA proposes temporary Schedule I placement for 7-hydroxymitragynine above a threshold, impacting manufacturers, distributors, and compounders handling this substance.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 16, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) that produce, distribute, or compound products containing 7-hydroxymitragynine above the specified threshold. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Effective date upon publication in Federal Register (typically 30 days after publication); comments due within 60 days of publication.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
7-hydroxymitragynine above a specified threshold will be temporarily placed in Schedule I, making it illegal to manufacture, distribute, or possess without DEA registration.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) that produce, distribute, or compound products containing 7-hydroxymitragynine above the specified threshold.
What you must do
Identify any products or ingredients containing 7-hydroxymitragynine above the threshold; cease all activities unless registered with DEA for Schedule I; submit comments or objections before the effective date.
Deadline
Effective date upon publication in Federal Register (typically 30 days after publication); comments due within 60 days of publication.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- IL HB0004: MEDICAID-PHARMACY SERVICES
- Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
- Determination That RECTIV (Nitroglycerin) Ointment, 0.4%, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Determination That Prednisolone Tablet, 5 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Determination That VASOPRESSIN IN SODIUM CHLORIDE (vasopressin) 0.9%, Injection, 50 units/50 milliliters (1 unit/milliliters) Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness